ID: ALA1243283

Max Phase: Preclinical

Molecular Formula: C27H25ClF2N8O2

Molecular Weight: 567.00

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNCc1cn(CCF)nn1

Standard InChI:  InChI=1S/C27H25ClF2N8O2/c1-2-40-25-12-23-20(27(17(13-31)14-33-23)34-18-5-6-22(30)21(28)10-18)11-24(25)35-26(39)4-3-8-32-15-19-16-38(9-7-29)37-36-19/h3-6,10-12,14,16,32H,2,7-9,15H2,1H3,(H,33,34)(H,35,39)/b4-3+

Standard InChI Key:  PLNCBERXTZFKGL-ONEGZZNKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 567.00

Molecular Weight (Monoisotopic): 566.1757

AlogP: 4.89

#Rotatable Bonds: 12

Polar Surface Area: 129.78

Molecular Species: NEUTRAL

HBA: 9

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.55

CX Basic pKa: 7.00

CX LogP: 3.85

CX LogD: 3.71

Aromatic Rings: 4

Heavy Atoms: 40

QED Weighted: 0.16

Np Likeness Score: -2.00

References

1. Pisaneschi F, Nguyen QD, Shamsaei E, Glaser M, Robins E, Kaliszczak M, Smith G, Spivey AC, Aboagye EO..  (2010)  Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation.,  18  (18): [PMID:20797871] [10.1016/j.bmc.2010.08.004]

Source

Source(1):

• Scientific Literature